Trained in Biochemistry and Cellular Biology at the University of Rome and the Italian National Institute of Health, I completed a PhD in Biochemistry at the University of Rome “La Sapienza” on the topic of DNA and RNA methylation in relation to muscle cell differentiation. After a short postdoctoral training in the National Institute of Health in Rome, I won an international post-doctoral fellowship from the Italian Association for Cancer Research (AIRC) and moved to the Kimmel Cancer Institute, Thomas Jefferson University Philadelphia. Working in the laboratory of Prof. Bruno Calabretta, I was the first to characterize the transcription factor and oncoprotein B-MYB and establish its relationship with key tumour suppressor genes, such as p53 and retinoblastoma family members. In 2001 I was recruited by the UCL Institute of Child Health as Senior Lecturer and later promoted to Reader. In UCL I continued to pursue the study of oncogenic transcription factors in the context of neuroblastoma, a childhood tumour affecting the peripheral nervous system. I was appointed Professor of Translational Cancer Research and Deputy Director of the Brunel Institute of Cancer Genetics and Pharmacogenomics in September 2011. In 2016 I joined the Synthetic Biology Theme in the Institute of Environment, Health and Societes.
Member of the Research Ethics Committe
Academic Appeal Commitee panel member
Newest selected publications
Andersson, MK., Mangiapane, G., Nevado, PT., Tsakaneli, A., Carlsson, T., Corda, G., (2020) 'ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma'. Oncogenesis, 9 (1). pp. 5. ISSN: 2157-9024 Open Access Linket al.
Karteris, E., Nieddu, V., Piredda, R., Bexel, D., Barton, J., Anderson, J., (2019) 'Engineered human mesenchymal stem cells for neuroblastoma therapeutics'. Oncology Reports, 42 (1). pp. 1 - 8. ISSN: 1021-335X Open Access Linket al.
Capone, E., Piccolo, E., Fichera, I., Ciufici, P., Barcaroli, D., Sala, A., (2017) 'Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.'. Oncotarget, 8 (36). pp. 60368 - 60377. ISSN: 1949-2553et al.
Sala, A. (2017) 'Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma'. Oncotarget, 8 (36). pp. 60368 - 60377. ISSN: 1949-2553 Open Access Link
Sala, A. and corda, G. (2017) 'Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage.'. Oncogenesis, 6 (7). pp. e364. ISSN: 2157-9024 Open Access Link